Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_assertion type Assertion NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_head.
- NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_assertion description "[Preliminary results from a pilot trial on trastuzumab's mechanism of action against operable breast tumors overexpressing Her2 suggested a role for antibody-dependent cell cytotoxicity (ADCC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_provenance.
- NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_assertion evidence source_evidence_literature NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_provenance.
- NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_assertion SIO_000772 18089830 NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_provenance.
- NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_assertion wasDerivedFrom befree-2016 NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_provenance.
- NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_assertion wasGeneratedBy ECO_0000203 NP646033.RAc1WUJC96w2ZH735WXoCp3hHrxuWLVuqG4HsPYnSF69U130_provenance.